Bristol Myers to discontinue trial for colorectal cancer treatment
Send a link to a friend
[December 16, 2023]
(Reuters) - Bristol Myers Squibb said on Friday it would
discontinue its late-stage trial testing a treatment for a type of colon
cancer.
The company said an independent data monitoring committee's analysis
showed the trial was unlikely to meet its primary endpoints upon
completion.
The trial was evaluating a combination therapy in patients who received
previous treatment for a kind of colorectal cancer.
The company said the therapy did not have any safety concerns and it
will be investigated as a treatment for other types of tumors.
(Reporting by Christy Santhosh; Editing by Maju Samuel and Shinjini
Ganguli)
[to top of second column]
|
![](../images/121623PIX/health93.jpg)
Test tubes are seen in front of a displayed Bristol Myers Squibb
logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File
Photo
![](http://archives.lincolndailynews.com/2023/Dec/16/images/ads/current/lincolnheating_lda_HFH_2023.png)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |